Taking stock of the drug industry, from the lab to the medicine chestFebruary 22, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Courtesy Tulane National Primate Research Center STAT+ | Charles River suspends shipments of monkeys used in research amid federal probe The move comes after several people were indicted last November for their alleged involvement in a monkey-smuggling operation. By Ed Silverman STAT+ | Biotech rents hold firm as demand for lab space slumps Rental rates haven't declined much as landlords still look to turn a profit on increasingly expensive development projects. By Jonathan Wosen STAT+ | Once high-flying Rubius to shut down. Its flameout is a lesson for biotech The flameout of Rubius, once valued at $2 billion, is the unsurprising result of a particularly ignominious biotech financing trend. By Adam Feuerstein Alex Hogan/STAT STAT+ | Moderna expands CRISPR gene editing research with ElevateBio partnership The same mRNA technology used in the Cambridge company's COVID vaccine could lead to permanent treatments for genetic diseases. By Ryan Cross — The Boston Globe More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments